Hello NewWorldCoiner,

Please see my paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC497566/pdf/0023-04.pdf; we have experience with the development of these tests. Our partners are the leading developer of lateral flow tests in Southern California. The lateral flow diagnostic technology has evolved substantially in the last 10 years. We are targeting technical improvements like this:https://www.nature.com/articles/srep28645.pdf and also this: http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0156866&type=printable. Bowhead Health is not similar to Theranos. We have a different approach to diagnostics as described above and also our business model creates value not only from accurate diagnostics but from the capacity to dispense supplements and medications in a personalized manner.

If you like to see our patent application. Please provide a name, address and a confidentiality agreements and we will send submission. The patent application supports the use of a diagnostic and a dispensing device and Bowhead Health business model as described above. We are a startup with a working prototype, a group of experts in diagnostics, medical informatics, robotics and manufacturing. The business is a work in progress, including the integration of blockchain medical informatics, diagnostics and personalized dispensing of required supplements.

There are several companies with diagnostics for malaria, but that is not our proposed core business.

There will be bugs and problems with our device and we are identifying those now. We will also have a  market beta test to identify other issues that we may not be aware at this point in time.